{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:07:27Z","timestamp":1790698047389,"version":"4.1.0"},"reference-count":34,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T00:00:00Z","timestamp":1665273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Mantle cell lymphoma (MCL) is an uncommon subcategory of non-Hodgkin lymphoma (NHL). Pathogenesis primarily includes overexpression of CCND1 and SOX11 along with other molecular aberrations. Lutetium 177Lu-DOTATATE is a radiolabeled somatostatin analogue used for the treatment of gastrointestinal neuroendocrine tumors. There are no clinical data supporting the use of Lutetium 177Lu-DOTATATE in the treatment of lymphoma. We describe the case of an 84-year-old man with a history of MCL and carcinoid tumor of the lung. Following progression of the carcinoid malignancy, the patient was treated with Lutetium 177Lu-DOTATATE. After treatment, there was an overall improvement of the patient\u2019s MCL that was demonstrated by stable lymphadenopathy on serial CT scans and down-trend of the absolute lymphocyte count. Therefore, we hypothesize that 177Lu-DOTATATE might have a role and can be repurposed for treating MCL.<\/jats:p>","DOI":"10.3390\/curroncol29100594","type":"journal-article","created":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T20:49:31Z","timestamp":1665348571000},"page":"7552-7557","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Repurposed Effect of 177Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma"],"prefix":"10.3390","volume":"29","author":[{"given":"Mohamad K.","family":"Elajami","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena P.","family":"Burton","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham F.","family":"Bahmad","sequence":"additional","affiliation":[{"name":"Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7798-9409","authenticated-orcid":false,"given":"Gerard","family":"Chaaya","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology and Oncology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology and Oncology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajh.25487","article-title":"Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management","volume":"94","author":"Jain","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-020-00914-1","article-title":"Emerging therapies in mantle cell lymphoma","volume":"13","author":"Hanel","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/17474124.2019.1685381","article-title":"(177)Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors","volume":"13","author":"Das","year":"2019","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Hennrich, U., and Kopka, K. (2019). Lutathera(\u00ae): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals, 12.","DOI":"10.3390\/ph12030114"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"13946","DOI":"10.1038\/s41598-017-14222-1","article-title":"Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells","volume":"7","author":"Body","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood-2007-06-093401","article-title":"Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma","volume":"111","author":"Ek","year":"2008","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00277-020-03956-0","article-title":"Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry","volume":"99","author":"Hohloch","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.beha.2012.04.004","article-title":"Radioimmunotherapy in mantle cell lymphoma","volume":"25","author":"Skarbnik","year":"2012","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jamainternmed.2014.5756","article-title":"The withdrawal of drugs for commercial reasons: The incomplete story of tositumomab","volume":"174","author":"Prasad","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/EJE-14-0488","article-title":"GEPNETs update: Radionuclide therapy in neuroendocrine tumors","volume":"172","author":"Bodei","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/1097-0215(20010601)92:5<628::AID-IJC1244>3.0.CO;2-L","article-title":"[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy","volume":"92","author":"Breeman","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.2174\/092986732811210416084626","article-title":"Drug Repurposing in Cancer: Now and Beyond","volume":"28","author":"Eid","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fonc.2017.00273","article-title":"Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs as Cancer Therapeutics","volume":"7","author":"Hernandez","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.bbcan.2019.04.005","article-title":"Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer","volume":"1871","author":"Scapozza","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"De Lellis, L., Veschi, S., Tinari, N., Mokini, Z., Carradori, S., Brocco, D., Florio, R., Grassadonia, A., and Cama, A. (2021). Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates. Cancers, 13.","DOI":"10.3390\/cancers13163946"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1369\/00221554211025482","article-title":"Repurposing of Anticancer Stem Cell Drugs in Brain Tumors","volume":"69","author":"Bahmad","year":"2021","journal-title":"J. Histochem. Cytochem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10555-019-09840-2","article-title":"Drug repurposing towards targeting cancer stem cells in pediatric brain tumors","volume":"39","author":"Bahmad","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/bjh.14878","article-title":"Clarithromycin as a \u201crepurposing drug\u201d against MALT lymphoma","volume":"182","author":"Ferreri","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2141.2010.08179.x","article-title":"Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: Final results of a single-centre phase II trial","volume":"150","author":"Govi","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2174\/1386207322666190916120128","article-title":"Drug Repurposing Screen Identifies Novel Classes of Drugs with Anticancer Activity in Mantle Cell Lymphoma","volume":"22","author":"Han","year":"2019","journal-title":"Comb. Chem. High Throughput Screen"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"710900","DOI":"10.3389\/fonc.2021.710900","article-title":"Somatostatin Receptors and Chemokine Receptor CXCR4 in Lymphomas: A Histopathological Review of Six Lymphoma Subtypes","volume":"11","author":"Juntikka","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1093\/annonc\/12.suppl_2.S125","article-title":"Neuroendocrine aspects of immunolymphoproliferative diseases","volume":"12","author":"Ferone","year":"2001","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/08820138609094136","article-title":"Gastrointestinal regulatory peptides modulate mouse lymphocyte functions under serum-free conditions in vitro","volume":"15","author":"Krco","year":"1986","journal-title":"Immunol. Invest."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0008-8749(84)90117-5","article-title":"Inhibition by somatostatin of the proliferation of T-lymphocytes and Molt-4 lymphoblasts","volume":"84","author":"Payan","year":"1984","journal-title":"Cell Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4049\/jimmunol.136.1.152","article-title":"Differential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferations by lymphocytes from Peyer\u2019s patches, mesenteric lymph nodes, and spleen","volume":"136","author":"Stanisz","year":"1986","journal-title":"J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0008-8749(85)90183-2","article-title":"The mechanism of antibody-dependent cellular cytotoxicity stimulation by somatostatin in rat peritoneal macrophages","volume":"90","author":"Gyimesi","year":"1985","journal-title":"Cell Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1210\/jcem-63-2-433","article-title":"High incidence of somatostatin receptors in human meningiomas: Biochemical characterization","volume":"63","author":"Reubi","year":"1986","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ijc.2910460315","article-title":"Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: Relationship to EGF receptors","volume":"46","author":"Reubi","year":"1990","journal-title":"Int. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ijc.2910450211","article-title":"Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: Relationship to EGF-receptors","volume":"45","author":"Reubi","year":"1990","journal-title":"Int. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ijc.2910500613","article-title":"In Vitro and in vivo detection of somatostatin receptors in human malignant lymphomas","volume":"50","author":"Reubi","year":"1992","journal-title":"Int. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1182\/blood-2008-10-185827","article-title":"Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): Importance for interactions with the stromal microenvironment and specific targeting","volume":"113","author":"Kurtova","year":"2009","journal-title":"Blood"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/10\/594\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:48:57Z","timestamp":1760143737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/10\/594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,9]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["curroncol29100594"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29100594","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,9]]}}}